Dhingra Kapil sold $408K of REPL

Dhingra Kapil sold 21,500 shares of Replimune Group, Inc. (REPL) at $19.00 ($0.41M total) on 2026-11-02.

Original reporting
SEC EDGAR · Dhingra Kapil
Published Nov 4, 2026, 1:43 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 4, 2026, 2:02 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$REPL
Bearish
high confidence
Mentioned
$REPL
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$REPLBearishLow
01

Why it matters

The disclosed sale reduces insider ownership, which may be interpreted as reduced confidence, prompting short sellers.

02

Market read

Primary insider sale filing; modest size but notable for a micro‑cap, offering a low‑actionability trading signal.

03

What to watch

Potential upcoming clinical data releases or partnership news that could offset the negative signal.

Relevance 4/10Novelty 4/10Timing: post‑market filing on 2026‑11‑03

Background

SEC Form 4 filing discloses insider transactions. Directors' sales are monitored for signals about company outlook.

Company-level read

Ticker impact

$REPLBearishHigh confidence
Context

Director Kapil Dhingra sold 21,500 shares for $408,500, reducing his stake to 21,669 shares.

Expected impact

likely slight downward pressure as the market prices the insider sell

Evidence & confidence

Form 4 is a primary source; a $408k sale by a director is material for a micro‑cap and can trigger short‑term selling.

Market effects

Minimal; the sale is company‑specific and does not affect the broader biotech sector.

None; REPL trades on US exchanges only.

Low; limited to investors tracking REPL.

Counterpoint

The sale could be a routine liquidity event unrelated to fundamentals, so price may remain stable.

Key entities

  • Replimune Group, Inc.

    Biotech firm developing oncolytic virus therapies.

  • Kapil Dhingra

    Director of Replimune Group, Inc.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$REPLHigh

Replimune Soars 17% as TUDRIQEV Melanoma Launch Draws “Enthusiastic” Response From Physicians

Replimune (REPL) shares rose 17% after reporting strong initial uptake of TUDRIQEV, its melanoma treatment, with over 15 institutions prescribing it in three weeks. The company has $307.8 million in cash. TUDRIQEV is used with Bristol Myers Squibb's (BMY) Opdivo and targets tumors not treated by Amgen's (AMGN) Imlygic. Analysts expect revenue growth, but no sales figures are available yet.

$REPLMed

Replimune (REPL) Q2 2027 Earnings Call Transcript

Replimune (REPL) reported Q2 2027 earnings, highlighting the commercial launch of TUDRIQEV. The company noted strong physician interest and rapid adoption, with over 15 institutions prescribing the drug in less than 20 business days. Replimune reported a net loss of $57.1 million for the quarter, with $307.8 million in cash reserves. The company expects to report first product revenue in Q3 2027.

$GMABHighAI 8/10

Biotech Stocks Rise: GMAB Surges, LUNG And AXGN Gain Over 30%

Genmab (GMAB) shares rose 33% after reporting positive Phase 3 results for its cancer drug. Pulmonx (LUNG) and Axogen (AXGN) shares gained over 30% on strong quarterly results. OrthoPediatrics (KIDS) and Replimune (REPL) also reported improved financials, driving their stock prices up. Specific financial data and guidance were provided by each company.

$REPLMed

Replimune Reports Fiscal Q2 2027 Results, $57.1 Million Net Loss

Replimune reported a net loss of $57.1M for Q2 2027, down from $83.1M a year earlier. Cash reserves were $307.8M. R&D and operating expenses decreased. TUDRIQEV, for advanced melanoma, launched commercially in the U.S. in October, with over 15 institutions prescribing it. The company is engaging with priority accounts and advancing clinical trials.